Analysts Set Expectations for TCRX FY2029 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at HC Wainwright issued their FY2029 earnings per share estimates for shares of TScan Therapeutics in a research note issued to investors on Thursday, March 6th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of $0.44 for the year. HC Wainwright currently has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share.

Several other analysts also recently issued reports on the company. Needham & Company LLC lowered their price target on TScan Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a report on Wednesday, March 5th. Barclays lowered their target price on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research note on Friday. Finally, Wedbush reissued an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, TScan Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $9.20.

TScan Therapeutics Trading Down 2.2 %

Shares of TScan Therapeutics stock traded down $0.04 during trading hours on Friday, hitting $1.82. The company's stock had a trading volume of 320,269 shares, compared to its average volume of 312,493. The business has a fifty day moving average of $2.38 and a 200 day moving average of $3.96. TScan Therapeutics has a 1-year low of $1.72 and a 1-year high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $97.14 million, a PE ratio of -1.72 and a beta of 0.91.

Remove Ads

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $0.67 million during the quarter, compared to analysts' expectations of $1.43 million.

Institutional Trading of TScan Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new stake in TScan Therapeutics during the 4th quarter valued at approximately $32,000. Prudential Financial Inc. purchased a new position in shares of TScan Therapeutics during the 4th quarter valued at approximately $32,000. ProShare Advisors LLC acquired a new stake in shares of TScan Therapeutics during the fourth quarter worth approximately $40,000. Wells Fargo & Company MN increased its stake in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after buying an additional 5,694 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in TScan Therapeutics in the fourth quarter valued at $59,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.